186 related articles for article (PubMed ID: 26670887)
1. Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.
Peredo I; Helldén A; Wolmer-Solberg N; Pohanka A; Stragliotto G; Rahbar A; Ståhle L; Bellander BM; Söderberg-Nauclér C
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26670887
[TBL] [Abstract][Full Text] [Related]
2. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
5. Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature.
Seidel V; Feiterna-Sperling C; Siedentopf JP; Hofmann J; Henrich W; Bührer C; Weizsäcker K
Med Microbiol Immunol; 2017 Oct; 206(5):347-354. PubMed ID: 28733760
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection.
Zhang B; Fila M; Fakhoury M; Baudouin V; Deschênes G; Jacqz-Aigrain E; Zhao W
J Antimicrob Chemother; 2014 Apr; 69(4):1150-1. PubMed ID: 24252753
[No Abstract] [Full Text] [Related]
8. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
9. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.
Lombardi G; Garofoli F; Villani P; Tizzoni M; Angelini M; Cusato M; Bollani L; De Silvestri A; Regazzi M; Stronati M
Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1465-70. PubMed ID: 19763643
[TBL] [Abstract][Full Text] [Related]
10. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N
Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.
Lefeuvre S; Chevalier P; Charpentier C; Zekkour R; Havard L; Benammar M; Amrein C; Boussaud V; Lillo-Le Louët A; Guillemain R; Billaud EM
Transpl Infect Dis; 2010 Jun; 12(3):213-9. PubMed ID: 20102551
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
18. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
[TBL] [Abstract][Full Text] [Related]
19. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.
Meine Jansen CF; Toet MC; Rademaker CM; Ververs TF; Gerards LJ; van Loon AM
J Perinat Med; 2005; 33(4):364-6. PubMed ID: 16211780
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
